A drug that will help the most severely affected patients with multiple sclorosis has been approved for use in Scotland.
The Scottish Medicines Consortium, which licences new treatments in Scotland, said that the drug Fingolimod would be available from this week.
It comes only months after the SMC had refused to allow the drug to be available on prescription despite it being available in England and Wales.
In March, the SMC had told the drug's manufacturers Novaris UK, they would have to reduce the cost before they could approve it.
Fingolimod is already available in more than 60 other countries.
Following re-negotiations with the drug company, the SMC said the drug was now more "cost effective".
MS is a neurological condition which affects around 10,000 people living in Scotland.
Symptoms include numbness and mobility problems.
Local NHS boards in Scotland have welcomed the introduction of the drug north of the border.
MS patient Gillian Rafferty, aged 48, who lives in Moffat and has been taking the drug as part of a clinical trial for five years, said that Fingolimod had transformed her life.
She said she was pleased that the drug was now available to all those who need it but said patients should be allowed to take it straight away without first having to try other medications.